Ruxolitinib is a Janus kinase (JAK) inhibitor used to treat certain types of blood cancers, such as myelofibrosis and polycythemia vera. It works by blocking the activity of JAK1 and JAK2 enzymes, which are involved in the signaling pathways that control the growth of blood cells. Ruxolitinib helps reduce symptoms like splenomegaly (enlarged spleen) and improve overall survival rates.
Cleanchem is a trusted provider of premium pharmaceutical reference materials, specializing in Ruxolitinib and its associated compounds. Our catalog includes pharmacopeial and non-pharmacopeial Ruxolitinib impurities, metabolites, nitrosamine derivatives (N-NO compounds), and stable isotope-labeled products. These reference standards play a critical role in pharmaceutical R&D, supporting activities such as product formulation, ANDA and DMF submissions, quality assurance, analytical method development, and stability assessments.
All Ruxolitinib-related substances undergo comprehensive characterization and are delivered with complete Certificates of Analysis and supporting analytical documentation to ensure regulatory adherence. Upon request, we can offer EP/USP traceable standards. Our products are routinely re-evaluated to maintain consistent quality and performance.
English
Arabic
Chinese (Simplified)
French
Japanese
Portuguese
Russian
Spanish
